Stable Latent HIV Infection and Low-Level Viremia Despite Treatment with the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.

We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received two month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T cell-associated HIV RNA (rca-RNA), intact proviral DNA assay (IPDA), and quantitative viral outgrowth assay (QVOA) were measured at baseline and post-treatment. In three participants, IPDA and QVOA declines were accompanied by significant declines of rca-RNA. However, no IPDA or QVOA declines clearly exceeded assay variance or natura decay. Increased resistance to VRC07-523LS was not observed. This combination therapy did not reduce viremia or the HIV reservoir.